Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan
This license will enable Abbott to enhance access to this novel therapy to more patients across India
This license will enable Abbott to enhance access to this novel therapy to more patients across India
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Subscribe To Our Newsletter & Stay Updated